BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Verburg FA, Amthauer H, Binse I, Brink I, Buck A, Darr A, Dierks C, Koch C, König U, Kreissl MC, Luster M, Reuter C, Scheidhauer K, Willenberg HS, Zielke A, Schott M. Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives. Horm Metab Res 2021;53:149-60. [PMID: 33652491 DOI: 10.1055/a-1380-4154] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Su J, Wang M, Fu Y, Yan J, Shen Y, Jiang J, Wang J, Lu J, Zhong Y, Lin X, Lin Z, Lin S. Efficacy and safety of multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer: a systematic review and meta-analysis of clinical trials. Expert Rev Anticancer Ther 2022. [PMID: 35833358 DOI: 10.1080/14737140.2022.2102000] [Reference Citation Analysis]
2 Jones H, Green V, England J, Greenman J. Current understanding of nonsurgical interventions for refractory differentiated thyroid cancer: a systematic review. Future Sci OA 2021;7:FSO738. [PMID: 34258030 DOI: 10.2144/fsoa-2021-0041] [Reference Citation Analysis]
3 Ratajczak M, Gaweł D, Godlewska M. Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update. Int J Mol Sci 2021;22:11829. [PMID: 34769260 DOI: 10.3390/ijms222111829] [Reference Citation Analysis]
4 Kaae AC, Kreissl MC, Krüger M, Infanger M, Grimm D, Wehland M. Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer-Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension. Int J Mol Sci 2021;22:12217. [PMID: 34830100 DOI: 10.3390/ijms222212217] [Reference Citation Analysis]